Case report of a primary effusion lymphoma successfully treated with oral valganciclovir after failing chemotherapy.
Juan Marquet PalomanesKyra Velazquez-KennedySandra LópezAmparo BenitoMaría-Jesús BlanchardJose Antonio Garcia-VelaPublished in: Hematological oncology (2017)
Primary effusion lymphoma is a rare non-Hodgkin lymphoma that presents with pleural effusions and lacking of tumour mass. It is universally associated with human herpesvirus 8 (HHV8) and is more frequent among immunosuppressed patients. There is no standard treatment, chemotherapy and anti-HIV therapy have been used with poor results, but there is still no strong evidence supporting the use of valganciclovir. We present the case of a HIV positive man that presented with pleural effusion compatible with primary effusion lymphoma and positivity for HHV8 DNA in blood. Bortezomib-containing treatment protocol was started, but the disease progressed within the chemotherapy. Therefore, treatment with oral valganciclovir was decided and the patient achieved a sustained radiological complete response. HHV8 DNA turned negative 6 months after starting the treatment with valganciclovir.
Keyphrases
- hiv positive
- case report
- antiretroviral therapy
- randomized controlled trial
- newly diagnosed
- human immunodeficiency virus
- south africa
- squamous cell carcinoma
- radiation therapy
- men who have sex with men
- single molecule
- hepatitis c virus
- circulating tumor
- prognostic factors
- chronic kidney disease
- cell free
- bone marrow
- patient reported outcomes
- patient reported
- pluripotent stem cells